Aktienanalyse zu XORTX Therapeutics Inc (XRTX)

$0.870

-0.047 (-5.43%)Zum Schluss

Loading chart…

Hoch: 0.945
Eröffnung: 0.900
Volumengewichteter Durchschnittskurs: 0.89
Volumen: 13.36K
Marktkap.: 5.59M
Tief: 0.860
Umsatz: 11.91K
EV/EBITDA, TTM: 0.00

XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

www.xortx.com

KI-Analyse of XORTX Therapeutics Inc (XRTX)

Verkaufen

XORTX Therapeutics Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The stock is currently priced at $0.87, which is close to its 52-week low of $0.83, indicating weak market performance. Additionally, the RSI is at a low 24.41, suggesting the stock is oversold, but this does not guarantee a rebound. The company has reported a staggering year-to-date change of -69.47% and has a forward P/E ratio of 0.9621, indicating potential undervaluation but also reflecting ongoing financial struggles. The main risk is its negative net income, which reached -1,690,734 USD in Q2 2026, highlighting ongoing financial instability.

Bewertungskennzahlen

Das aktuelle erwartete KGV von XORTX Therapeutics Inc (XRTX) beträgt 0.96, verglichen mit dem 5-Jahres-Durchschnitt von -0.97.

Erwartetes KGV

Überbewertet

5J-Durchschnitt P/E

-0.97

Aktuelles P/E

0.96

Überbewertet

0.17

Unterbewertet

-2.12

Erwartetes EV/EBITDA

Fair bewertet

5J-Durchschnitt EV/EBITDA

0.08

Aktuelles EV/EBITDA

0.00

Überbewertet

0.33

Unterbewertet

-0.17

Erwartetes KUV

Fair bewertet

5J-Durchschnitt P/S

0.37

Aktuelles P/S

0.08

Überbewertet

1.34

Unterbewertet

-0.61

Alphio-AI-Kursszenarien für XRTX

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

Bullisch

Bullisch · 25%XRTX

$0.91

Szenariopreis

Basis

Basis · 50%XRTX

$0.82

Szenariopreis

Bärisch

Bärisch · 25%XRTX

$0.78

Szenariopreis